As indicated by preclinical trials, APRIL-CAR T cells effectively destroy tumor clones that express BCMA, TACI, or both the markers, which ensures a wider coverage of tumor heterogeneity [204]. This evidence concerns the gene TNFRSF17 and neoplasm.